Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.83 USD
+0.04 (4.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.82 -0.01 (-0.62%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Sangamo Therapeutics (SGMO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.80 | $8.00 | $1.00 | 357.83% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Sangamo Therapeutics comes to $3.80. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 381.01% from the last closing price of $0.79.
Analyst Price Targets (5 )
Broker Rating
Sangamo Therapeutics currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SGMO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 1.86 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Truist Securities | Nicole Germino | Hold | Hold |
8/7/2024 | Not Identified | Not Identified | Hold | Hold |
7/24/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
5/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
11/6/2023 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $3.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.07 |